By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
Biomarkers
Tumor Location and Tumor Sidedness
Fast facts:

What is tumor location or tumor sidedness?

Tumor location refers to the site of the primary tumor (tumour) of your colorectal cancer. The large intestine (bowel) is made up of 6 segments, cecum (caecum), ascending colon, transverse colon, descending colon, sigmoid colon, and rectum.

The hepatic flexure (right colic flexure) is the turning point between the ascending colon and transverse colon. The splenic flexure (left colic flexure) is the turning point between the transverse colon and descending colon.

Colorectal cancer (bowel cancer) can develop in any of these locations.

Often, colorectal cancer is referred to as “right sided” or “left sided”. This is the “sidedness” of the tumor. Right-sided tumors, also known as proximal tumors, are located in the cecum, ascending colon, hepatic flexure, or the first two-thirds of the transverse colon. Left-sided tumors, also called distal tumors, are located in the last third of the transverse colon, splenic flexure, descending colon, sigmoid colon, or rectum.

Tumor location is both a prognostic biomarker and a predictive biomarker. This means that tumor sidedness gives information about the likely course of the disease (prognosis), and tumor location is a predictor of which treatments may be more or less effective for a particular colorectal cancer.  

Why are right sided colon cancers and left sided colon and rectal cancers different?

Several factors likely contribute to the differences in right-sided colon cancers and left-sided colorectal cancers.

  • The right and left sides of the colon develop from two different parts of the embryo, the midgut and the hindgut.
  • As digested food travels through the large intestine, the right and left sides are exposed to different nutrients and digestive substances, such as bile acids.
  • The populations of normal gut bacteria (intestinal microbiome) that live in the large intestine vary between the right side of the colon and the left side of the colon and rectum. An increasing number of studies suggest that gut bacteria is related to colorectal cancer development.

How are right-sided colon cancer and left-sided colorectal cancer different?

Right-sided colon cancer has a better prognosis in early stages (stage I and stage II). Left-sided colon cancer has a better prognosis at advanced stages (stage III and stage IV / metastatic colorectal cancer).

How is tumor location or tumor sidedness determined?

The location of your colorectal cancer (CRC) may be identified in several ways. It may be described in imaging reports like CT scan, PET scan, or MRI scan. It can be noted in reports from surgical procedures like colonoscopy and colectomy (colon resection), or in pathology reports that describe the histology (microscopic characteristics) of your colorectal carcinoma.

How is tumor location or tumor sidedness reported?

Tumor location may be reported as “right-sided” or “left-sided”, or as “proximal” or “distal”. The specific location of your colorectal tumor will also be noted, such as splenic flexure, sigmoid colon, or rectum.  

How do my tumor location or tumor sidedness results impact my treatment?

If your colorectal cancer is right-sided, also known as proximal, (located in the cecum, ascending colon, hepatic flexure, or first two-thirds of transverse colon)

  • Immunotherapy with immune checkpoint inhibitors, such as pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy), is often effective against right-sided colorectal cancer.
  • Immune checkpoint inhibitors use your own immune system to kill cancer cells by promoting stronger responses against cancer cells from white blood cells in your tumor (tumor-infiltrating lymphocytes).
  • Bevacizumab added to conventional chemotherapy is more effective than EGFR inhibitors combined with conventional chemotherapy in right-sided cancers.
  • Surgical treatment of right-sided colon cancer may involve the removal of your cecum, ascending colon and/or a part of the transverse colon.

If your colorectal tumor is left-sided, also known as distal, (located in the last third of the transverse colon, splenic flexure, descending colon, sigmoid colon, or rectum)

  • Adjuvant chemotherapy with fluorouracil based regimens (FOLFOX, FOLFIRI) is effective against left-sided colorectal cancer. Adjuvant therapy is a secondary treatment given after the primary treatment to prevent recurrence of the cancer. Usually this is drug therapy that treats cancer cells that may remain in the body after surgery.
  • Conventional chemotherapy combined with EGFR inhibitors like cetuximab (Erbitux) or panitumumab (Vectibix) is more effective than chemotherapy combined with bevacizumab (VEGF inhibitor) in left-sided cancers.
  • Surgical treatment of left-sided colon cancer may involve having part of your transverse, descending, and/or sigmoid colon removed. If your cancer is low in the sigmoid colon, you may also have part of your rectum removed. If your cancer originates in the rectum, you will have some or all of your rectum removed.

Additional targeted therapy treatment options may be indicated based on the results of other biomarker testing such as microsatellite stability (MSS) and microsatellite instability (MSI), RAS gene mutation status (KRAS or NRAS), BRAF mutation status, and HER2 amplification or overexpression status. Talk to your oncology healthcare team about further biomarker testing, and how your results can impact your treatment.

Who should be tested for tumor location / tumor sidedness?

Tumor location should be determined for all colorectal cancer patients at the time of diagnosis.

No items found.
Key Terms
Adjuvant therapy

Treatment given after the primary treatment, such as drug therapy or radiation after surgery. This prevents recurrence of the cancer by treating cancer cells that may remain in the body after surgery.

Adjuvant therapy
Treatment given after the primary treatment, such as drug therapy or radiation after surgery. This prevents recurrence of the cancer by treating cancer cells that may remain in the body after surgery.
Immune Checkpoint Inhibitors

A group of targeted therapy drugs that help the bodys own immune system kill cancer cells. Tumor cells may express proteins that turn off a checkpoint (like an on-off switch) in the immune system. Immune checkpoint inhibitors block the tumors ability to do that, and turn the switch back on, activating the immune system to target the cancer cells. Use of immune checkpoint inhibitors is a type of immunotherapy. There are two sub-classes of immune checkpoint inhibitor used to treat colorectal cancer, PD-1 inhibitors and CTLA-4 inhibitors. (A third type, PD-L1 inhibitors, is used to treat other cancers.) Nivolumab (Opdivo) and pembrolizumab (Keytruda) are PD-1 inhibitors. Ipilimumab (Yervoy) is a CTLA-4 inhibitor. Immune checkpoint inhibitor sub-classes are sometimes combined for treatment.

Immune Checkpoint Inhibitors
A group of targeted therapy drugs that help the bodys own immune system kill cancer cells. Tumor cells may express proteins that turn off a checkpoint (like an on-off switch) in the immune system. Immune checkpoint inhibitors block the tumors ability to do that, and turn the switch back on, activating the immune system to target the cancer cells. Use of immune checkpoint inhibitors is a type of immunotherapy. There are two sub-classes of immune checkpoint inhibitor used to treat colorectal cancer, PD-1 inhibitors and CTLA-4 inhibitors. (A third type, PD-L1 inhibitors, is used to treat other cancers.) Nivolumab (Opdivo) and pembrolizumab (Keytruda) are PD-1 inhibitors. Ipilimumab (Yervoy) is a CTLA-4 inhibitor. Immune checkpoint inhibitor sub-classes are sometimes combined for treatment.
Immunotherapy

Treatment that helps the bodys own immune system kill cancer cells.

Immunotherapy
Treatment that helps the bodys own immune system kill cancer cells.
Prognostic biomarker

A biomarker that gives information about the likely course and outcome of a disease.

Prognostic biomarker
A biomarker that gives information about the likely course and outcome of a disease.
Targeted therapy

Treatments that work on specific cancer cells, causing less damage to a patients normal cells. This can include drugs that inhibit the function of cancer growth genes and proteins, drugs that help a patients immune system recognize and kill cancer cells, or drugs that inhibit the development of a tumors blood supply.

Targeted therapy
Treatments that work on specific cancer cells, causing less damage to a patients normal cells. This can include drugs that inhibit the function of cancer growth genes and proteins, drugs that help a patients immune system recognize and kill cancer cells, or drugs that inhibit the development of a tumors blood supply.

What is a biomarker?

A biomarker is a piece of information about your health. Biomarkers include your blood pressure, your blood type, and cholesterol or blood sugar levels measured in a blood test. The biomarkers of cancer are also known as tumor markers.

This Tumor Location/Sidedness campaign is a part of the Know Your Biomarker program. Thank you to our sponsor for their support:

Explore the full list of sponsors supporting the Know Your Biomarker Program here.